四环生物：2025年营收3.4-3.6亿元，净利润亏损收窄

Core Viewpoint - The company expects revenue for 2025 to be between 340 million to 360 million yuan, an increase from 204 million yuan in the same period last year, while net profit attributable to shareholders is projected to be a loss of 30 million to 40 million yuan, improving from a loss of 110 million yuan in the previous year, indicating a year-on-year growth of 63.63% to 72.73% in net profit [1] Revenue Summary - The revenue growth is primarily driven by a significant increase in sales from the wholly-owned subsidiary, Chenwei Ecological Park [1] - The expected revenue for 2025 is projected to be between 340 million to 360 million yuan, compared to 204 million yuan in the previous year [1] Profit Summary - The improvement in net profit is attributed to a reduction in asset impairment losses and operating expenses, as well as effective cost control measures at the controlling subsidiary, Beijing Sihuan Biological Pharmaceutical [1] - The projected net loss for 2025 is between 30 million to 40 million yuan, a notable improvement from the previous year's loss of 110 million yuan [1] Risk Warning - Due to the negative net profit in 2024 and revenue below 300 million yuan, the company's stock will be subject to delisting risk warning starting April 30, 2025, and may face termination of listing if financial indicators meet specified conditions [1]